ReviewCancer science2019
Toward the development of true "off-the-shelf" synthetic T-cell immunotherapy.
Review in Cancer science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- T cells assemble lentivirus to solve local delivery of stable gene therapy.Scientific reports · 2026Article
- Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases.Journal of hematology & oncology · 2025Review
- Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies.Journal of hematology & oncology · 2024Review
- Genome editing iPSC to purposing enhancement of induce CD8 killer T cell function for regenerative immunotherapy.Inflammation and regeneration · 2024Review
- Mini-TCRs: Truncated T cell receptors to generate T cells from induced pluripotent stem cells.Molecular therapy. Methods & clinical development · 2023Article
- Engineering T Cell Development for the Next Generation of Stem Cell-Derived Immunotherapies.GEN biotechnology · 2023Review
- Lineage tracing of T cell differentiation from T-iPSC by 2D feeder-free culture and 3D organoid culture.Frontiers in immunology · 2023Article
- Immunotherapy approaches for hematological cancers.iScience · 2022Review
- Neurotoxicity Associated with Treatment of Acute Lymphoblastic Leukemia Chemotherapy and Immunotherapy.International journal of molecular sciences · 2022Review
- Induced pluripotent stem cell-based disease modeling and prospective immune therapy for coronavirus disease 2019.Cytotherapy · 2022Review
- Review
- Review
- Article
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy.Nature reviews. Clinical oncology · 2020Review
- Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications.Cells · 2020Review
- Induced pluripotent stem cells as a novel cancer vaccine.Expert opinion on biological therapy · 2019Review
- Toward the development of true "off-the-shelf" synthetic T-cell immunotherapy.Cancer science · 2019Review
- Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There?Cancer journal (Sudbury, Mass.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent outstanding clinical results produced by engineered T cells, including chimeric antigen receptors, have already facilitated further research that broadens their applicability. One such direction is to explore new T cell sources for allogeneic "off-the-shelf" adoptive immunotherapy. Human pluripotent stem cells could serve as an alternative cell source for this purpose due to their unique features of infinite propagation ability and pluripotency. Here, we describe the current state of engineered T cell transfer with the focus on cell manufacturing processes and the potentials and challenges of induced pluripotent stem cell-derived T cells as a starting material to construct off-the-shelf T-cell banks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.